BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BC Week In Review | Aug 22, 2016
Clinical News

VX-661: Phase III discontinued

Vertex said it will discontinue a 2-part, double-blind, international Phase III trial in about 150 CF patients with 1 copy of the delta F508 CFTR mutation and a second mutation that results in minimal CFTR...
BC Week In Review | Jun 27, 2016
Clinical News

GLPG2222: Phase I data

A double-blind, placebo-controlled, Belgian Phase I trial in about 40 healthy volunteers showed that single ascending doses of up to 800 mg oral GLPG2222 and once-daily ascending doses of up to 600 mg oral GLPG2222...
BC Week In Review | Feb 1, 2016
Clinical News

GLPG2222: Phase I started

Galapagos began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate single and multiple ascending doses of oral GLPG2222 in about 40 healthy volunteers. The trial start triggered a $10 million milestone payment to Galapagos...
BC Week In Review | Mar 30, 2015
Clinical News

VX-661: Phase II data

A double-blind, U.S. Phase II trial in 39 CF patients ages >=18 with 2 copies of the delta F508 CFTR mutation showed that once-daily 100 mg and twice-daily 50 mg VX-661 plus twice-daily 150 mg...
BC Week In Review | Aug 4, 2014
Clinical News

Lumacaftor: Phase II data

An 8-week, exploratory Phase II trial in 125 CF patients ages >=12 who have 1 copy of the delta F508 CFTR mutation showed that twice-daily 400 mg lumacaftor plus twice-daily 250 mg Kalydeco ivacaftor missed...
BC Week In Review | Jun 30, 2014
Clinical News

Lumacaftor: Phase III data

Vertex reported data from the identical, double-blind, international Phase III TRAFFIC and TRANSPORT trials in 1,108 CF patients ages >=12 who have 2 copies of the delta F508 CFTR mutation showing that once-daily 600 mg...
BC Week In Review | May 5, 2014
Clinical News

VX-661: Phase II data

A double-blind, placebo-controlled Phase II trial in 18 CF patients ages >=12 with both the delta F508 CFTR mutation and G551D CFTR mutation showed that once-daily 100 mg VX-661 plus patients' ongoing stable Kalydeco ivacaftor...
BC Week In Review | Oct 28, 2013
Clinical News

Lumacaftor: Completed Phase III enrollment

Vertex completed enrollment of about 559 CF patients ages >=12 years who are homozygous for the delta F508 CFTR mutation in the double-blind, placebo-controlled, international Phase III TRAFFIC trial evaluating once-daily 600 mg or twice-daily...
BC Week In Review | Oct 28, 2013
Company News

Vertex pulmonary news

Vertex said it does not intend to further develop VX-983, a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector that was in Phase I testing for CF in healthy volunteers. Vertex said it is...
Items per page:
1 - 10 of 24